Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)

Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)

Abstract Antibody drug conjugates (ADCs) have improved outcomes for patients with metastatic breast cancer (MBC), but there is little data about the sequential use of these agents. In this multicenter retrospective cohort study, we identified 84 patients with HER2-low MBC treated sequentially with t...

Full description

Saved in:
Bibliographic Details
Main Authors: Laura A. Huppert, Reshma Mahtani, Samantha Fisch, Naomi Dempsey, Sarah Premji, Angelina Raimonde, Saya Jacob, Laura Quintal, Michelle Melisko, Jo Chien, Ana Sandoval, Lauren Carcas, Manmeet Ahluwalia, Natasha Harpalani, Jenna Hoppenworth, Anne Blaes, Kelly Blum, Mi-Ok Kim, Dame Idossa, Ruta Rao, Karthik V. Giridhar, Hope S. Rugo
Format: Article
Language:English
Published: Nature Portfolio 2025-04-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-025-00748-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41523-025-00748-5

Similar Items